3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma BWAY

BrainsWay Ltd.

BWAY NASDAQ IL0011007189 Biotech & Pharma

Stock factsheet

TickerBWAY
ExchangeNASDAQ
ISINIL0011007189
WKN
SectorBiotech & Pharma
Size class Small Cap
Market capitalisation 610 Mio. USD As of 2026-08-03

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

BrainsWay is an Israeli medical technology company developing non-invasive brain stimulation therapies. Its core product is the Deep Transcranial Magnetic Stimulation (Deep TMS) system, used to treat psychiatric and neurological conditions including depression, obsessive-compulsive disorder and addiction. The company distributes its systems to clinics and treatment centres worldwide.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
BrainsWay Ltd.BWAY NASDAQ610 Mio. USD
AngioDynamics, Inc. ANGONASDAQ 611 Mio. USD
MiMedx Group, Inc MDXGNASDAQ 602 Mio. USD
CorMedix Inc. CRMDNASDAQ 591 Mio. USD
Neurogene Inc. NGNENASDAQ 629 Mio. USD
MapLight Therapeutics, Inc. MPLTNASDAQ 590 Mio. USD
AgomAb Therapeutics NV AGMBNASDAQ 634 Mio. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.